Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

PURPOSE: This trial assessed the safety, pharmacokinetics, and efficacy of darolutamide (ODM-201), a new-generation nonsteroidal androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: In this open-label, nonrandomized, two-cohort, do...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Nobuaki, Mukai, Hirofumi, Hosono, Ako, Onomura, Mai, Sasaki, Masaoki, Yajima, Yoko, Hashizume, Kensei, Yasuda, Masanobu, Uemura, Miho, Zurth, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686265/
https://www.ncbi.nlm.nih.gov/pubmed/28801852
http://dx.doi.org/10.1007/s00280-017-3417-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686265/
https://www.ncbi.nlm.nih.gov/pubmed/28801852
http://dx.doi.org/10.1007/s00280-017-3417-3

Ejemplares similares